GEMP GEMPHIRE THERAPEUTICS

Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15

Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15

LIVONIA, Mich., March 13, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that it will host a conference call and live audio webcast on Thursday, March 15, 2018 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2017 and to provide a business update.

Thursday, March 15 at 4:30pm Eastern Time 
Domestic:(844) 494-0188
International:+1 (425) 278-9114
Conference ID2090268
Webcast:

A webcast replay will be available on the News & Events section of the Gemphire website for all interested parties following the call and will be archived and available for 90 days.

About Gemphire

Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH.  The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins, that will benefit patients, physicians, and payors.  Gemphire’s Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, including FH and ASCVD, SHTG and NASH/NAFLD.  Two trials supporting hypercholesterolemia have been completed under NCT02722408 and NCT02634151.  Gemphire has completed recruitment for a clinical trial for SHTG under NCT02944383, and has initiated separate trials for adult NASH and pediatric NAFLD. Please visit  for more information.

Contact:

Andrew McDonald, Ph.D.

LifeSci Advisors, LLC

(646) 597-6987

Jeff Mathiesen, CFO

Gemphire Therapeutics Inc.

(734)-245-1700

 

EN
13/03/2018

Underlying

GEMPGEMPHIRE THERAPEUTICS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GEMPHIRE THERAPEUTICS

 PRESS RELEASE
Free
GEMP GEMPHIRE THERAP...

Gemphire Therapeutics Announces Expected Closing Date of Merger with N...

Gemphire Therapeutics Announces Expected Closing Date of Merger with NeuroBo Pharmaceuticals ANN ARBOR, Mich., Dec. 30, 2019 (GLOBE NEWSWIRE) -- The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is currently expected to close after market hours today, Monday, December 30, 2019, subject to satisfaction or waiver of all closing conditions. As previously announced, Gemphire’s stockholders voted to approve the proposals required to complete the merger transaction. In connection with these approvals, the Board of Directors of Gemphire has ap...

December 30, 2019 1 EN
 PRESS RELEASE
Free
GEMP GEMPHIRE THERAP...

Gemphire Therapeutics Announces Stockholder Approval of Proposals Requ...

Gemphire Therapeutics Announces Stockholder Approval of Proposals Required for Merger with NeuroBo Pharmaceuticals ANN ARBOR, Mich., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held December 6, 2019, its stockholders approved all of the merger-related proposals, including: (i) the issuance of Gemphire common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated July 24, 2019, by and among Gemp...

December 6, 2019 1 EN
 PRESS RELEASE
Free
GEMP GEMPHIRE THERAP...

Gemphire Therapeutics Reports Second Quarter 2019 Financial Results an...

Gemphire Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update LIVONIA, Mich., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications, as well as nonalcoholic fatty liver disease (NAFLD/NASH), today announced financial results for the quarter and six months ended June 30, 2019, and provided a ...

August 9, 2019 1 EN
 PRESS RELEASE
Free
GEMP GEMPHIRE THERAP...

Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agre...

Gemphire Therapeutics and NeuroBo Pharmaceuticals Announce Merger Agreement to Advance a Neurodegenerative Disease Company Transaction to Create Nasdaq-listed Biotechnology Company Focused on Advancing NeuroBo’s Clinical-Stage Pipeline NeuroBo Poised to Advance Lead Drug Candidate into Phase 3 Trials for Neuropathic Pain Indications NeuroBo Recently Received Aggregate Gross Proceeds of $24.24 Million in Series B Financing Gemphire Out-Licenses Gemcabene to Beijing SL Pharmaceutical Co. for Chinese Market Companies to Host Conference Call at 8:30 a.m. ET on July 25, 2019 LIVONIA, Mich...

July 24, 2019 1 EN
 PRESS RELEASE
Free
GEMP GEMPHIRE THERAP...

Gemphire Announces Top-Line Data from Familial Partial Lipodystrophy (...

Gemphire Announces Top-Line Data from Familial Partial Lipodystrophy (FPLD) Phase 2a Proof-of-Concept NAFLD/NASH Clinical Trial Gemcabene safely lowered serum triglycerides (TGs), the primary endpoint, in a subset of FPLD patients LIVONIA, Mich., June 26, 2019 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP) today announced top-line results based upon the Company’s preliminary review of the limited top-line dataset from the investigator-led Phase 2a study of adult FPLD patients evaluating efficacy, safety, and tolerability of oral gemcabene. Five FPLD patients were enrolle...

June 26, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch